

Appendix 10. Research Gaps in Pediatric Fever and Neutropenia

| |
|--|
| Identification of a validated high-risk stratification schema for pediatric fever and neutropenia |
| Determination of the incremental value of a peripheral blood culture in addition to central venous catheter cultures of an adequate volume in children with fever and neutropenia |
| Identification of the optimal type and frequency of re-evaluation (for example, daily or every second day telephone contact or clinic visit) for pediatric outpatients with low-risk fever and neutropenia |
| Determination of the optimal treatment regimen for microbiologically documented sterile site infections during fever and neutropenia |
| Identification of the optimal frequency of blood culture sampling in persistently febrile pediatric patients with neutropenia who are either clinically stable or unstable |
| Determination of the optimal duration of antibiotic therapy for patients with high-risk fever and neutropenia without bone marrow recovery for prolonged periods |
| Determination of whether a strategy of routine galactomannan screening in IFD high-risk children is cost-effective and results in better clinical outcomes compared to a strategy without screening |
| Determination of the clinical utility and optimal cut-off of β -D-glucan testing in IFD high-risk children |
| Determination of the clinical utility of routine sinus imaging in children being evaluated for IFD |
| Determination of the safety and efficacy of a pre-emptive antifungal approach in IFD low-risk and IFD high-risk children |
| Identification of the optimal investigation and treatment for viral infections in children with fever and neutropenia |

Abbreviation: IFD – invasive fungal disease